NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Forecast, Price & News

$111.99

+0.42 (+0.38%)

(As of 10/3/2023 ET)

Compare

Today's Range: $110.13
▼
$112.63
50-Day Range: $108.51
▼
$130.22
52-Week Range: $61.11
▼
$132.68

Volume: 266,677 shs
Average Volume: 326,948 shs
Market Capitalization: $3.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $137.57

Krystal Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 22.8% Upside
$137.57 Price Target
Short Interest: Bearish
5.68% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.44
Based on 3 Articles This Week
Insider Trading: Selling Shares
$3.18 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.08) to ($1.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

681st out of 966 stocks

Biological Products, Except Diagnostic Industry

92nd out of 144 stocks

2.5

Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $137.57, Krystal Biotech has a forecasted upside of 22.8% from its current price of $111.99.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.68% of the outstanding shares of Krystal Biotech have been sold short.
Short Interest Ratio / Days to Cover
Krystal Biotech has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in Krystal Biotech has recently increased by 6.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Krystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Krystal Biotech is -0.87.

1.4

News and Social Media Coverage

News Sentiment
Krystal Biotech has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Krystal Biotech this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,180,750.00 in company stock.
Percentage Held by Insiders
17.00% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.30% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to grow in the coming year, from ($5.08) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -20.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -20.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Price History

30 days | 90 days | 365 days | Advanced Chart

KRYS Stock News Headlines

October 3, 2023 | americanbankingnews.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update

September 28, 2023 | finance.yahoo.com

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

October 4, 2023 | Oxford Club (Ad)

The #1 Energy Passive Income Investment for 2023

It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.

September 25, 2023 | finance.yahoo.com

Krystal Biotech, Inc. (NASDAQ:KRYS): Are Analysts Optimistic?

September 24, 2023 | americanbankingnews.com

Krystal Biotech (NASDAQ:KRYS) Stock Price Down 2.3%

September 22, 2023 | msn.com

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

September 22, 2023 | msn.com

Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement

September 21, 2023 | seekingalpha.com

Krystal Biotech wins FDA nod to run trial for gene therapy

October 4, 2023 | Oxford Club (Ad)

The #1 Energy Passive Income Investment for 2023

It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.

September 21, 2023 | markets.businessinsider.com

Krystal Biotech Announces FDA Clearance Of IND For KB408

September 15, 2023 | msn.com

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?

September 13, 2023 | msn.com

Krystal Biotech CEO sells shares worth $6.3M

September 13, 2023 | finance.yahoo.com

Insider Sell: Suma Krishnan Sells 50,000 Shares of Krystal Biotech Inc (KRYS)

September 7, 2023 | msn.com

Berenberg starts Krystal Biotech at buy, cites upcoming drug launch

September 7, 2023 | msn.com

Berenberg Initiates Coverage of Krystal Biotech (KRYS) with Buy Recommendation

September 7, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Krystal Biotech

September 7, 2023 | finance.yahoo.com

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 5, 2023 | msn.com

Krystal Biotech gets FDA orphan drug designation for AATD drug candidate

September 5, 2023 | markets.businessinsider.com

Krystal Biotech: FDA Grants Orphan Drug Designation For KB408

September 5, 2023 | finance.yahoo.com

Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

August 31, 2023 | msn.com

Krystal Biotech (KRYS) Price Target Increased by 8.11% to 151.54

August 22, 2023 | finance.yahoo.com

Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher

August 21, 2023 | markets.businessinsider.com

Krystal Biotech Completes Sale Of Rare Pediatric Disease Priority Review Voucher

August 21, 2023 | msn.com

Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M

August 21, 2023 | finance.yahoo.com

Krystal Biotech sells priority review voucher for $100M

August 21, 2023 | finance.yahoo.com

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

August 9, 2023 | msn.com

Chardan Capital Maintains Krystal Biotech (KRYS) Buy Recommendation

See More Headlines

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings: 8/07/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRYS
CUSIP: N/A
CIK: 1711279
Web: www.krystalbio.com
Phone: (412) 586-5830
Fax: N/A
Employees: 210
Year Founded: 2017

Price Target and Rating

Average Stock Price Forecast: $137.57
High Stock Price Forecast: $154.00
Low Stock Price Forecast: $118.00
Forecasted Upside/Downside: +22.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-139,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -25.46%
Return on Assets: -23.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.25
Quick Ratio: 20.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $20.28 per share
Price / Book: 5.52

Miscellaneous

Outstanding Shares: 27,990,000
Free Float: 23,235,000
Market Cap: $3.13 billion
Optionable: Not Optionable
Beta: 0.85

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Krish S. Krishnan M.B.A. (Age 58)
M.S., Founder, Chairman, Pres & CEO
Comp: $1.07M

Ms. Suma M. Krishnan (Age 58)
Founder, COO, Pres of R&D and Director
Comp: $789.92k

Ms. Kathryn A. Romano (Age 41)
Exec. VP & Chief Accounting Officer
Comp: $528.87k

Ms. Meg Dodge
VP of Investor Relations & Corp. Communications

Mr. John Karakkal
VP of North American Sales & Marketing

Mr. Josh Suskin
Director of HR & Operations

Dr. Hubert C. Chen M.D. (Age 54)
Sr. VP of Clinical Devel.

Mr. Laurent Goux
Sr. VP & GM of Europe

Mr. Ram Kamineni
Sr. VP of CMC & Technical Operations

Mr. David Chien
Sr. VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.
What is Krystal Biotech's stock price forecast for 2023?: 7 Wall Street analysts have issued 1 year target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $118.00 to $154.00. On average, they anticipate the company's share price to reach $137.57 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.
How have KRYS shares performed in 2023?: Krystal Biotech's stock was trading at $79.22 at the beginning of 2023. Since then, KRYS shares have increased by 41.4% and is now trading at $111.99.
View the best growth stocks for 2023 here.
Are investors shorting Krystal Biotech?: Krystal Biotech saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,590,000 shares, an increase of 6.0% from the August 31st total of 1,500,000 shares. Based on an average trading volume of 268,500 shares, the short-interest ratio is presently 5.9 days.
View Krystal Biotech's Short Interest.
When is Krystal Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our KRYS earnings forecast.
How were Krystal Biotech's earnings last quarter?: Krystal Biotech, Inc. (NASDAQ:KRYS) announced its earnings results on Monday, August, 7th. The company reported ($1.25) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.02.
What ETFs hold Krystal Biotech's stock?: ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML).

What other stocks do shareholders of Krystal Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).
When did Krystal Biotech IPO?: (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
What is Krystal Biotech's stock symbol?: Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How do I buy shares of Krystal Biotech?: Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Krystal Biotech's stock price today?: One share of KRYS stock can currently be purchased for approximately $111.99.
How much money does Krystal Biotech make?: Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $3.13 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.43) on an earnings per share basis.
How many employees does Krystal Biotech have?: The company employs 210 workers across the globe.
How can I contact Krystal Biotech?: Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial